Eculizumab - Open Access .click

Results 141 to 150 of about 24,516 (282)

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Therapeutic Advances in Hematology, 2019
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert M. Stern, Nathan T. Connell
doaj +1 more source

Atypical haemolytic-uraemic syndrome caused by factor H mutation: case report and new management strategies in children [PDF]

, 2012
Atypical haemolytic uraemic syndrome is causedby alternative complement pathway dysregulation. It has recently been recognised that most cases are due to genetic factors and a growing list of mutations has been described.
Araújo, L. +5 more
core

POSB56 Cost-Effectiveness of Satralizumab Compared to Eculizumab for the Treatment Neuromyelitis Optica Spectrum Disorders (NMOSD) in Adult and Adolescent Patients Who Are Anti-Aquaporin 4 (AQP4) Seropositive in Canada [PDF]

, 2022
Carlos Martín de Vicente +5 more
openalex +1 more source

Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies

Journal of Comparative Effectiveness Research
What is this summary about? Neuromyelitis optica spectrum disorder (NMOSD for short) is a rare autoimmune health condition, meaning that the body’s natural defense system (the immune system) attacks the body’s own tissues.
Alfredo Damasceno, Mariano Marrodan
doaj +1 more source

Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome [PDF]